Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oculus Innovative Sciences

This article was originally published in The Gray Sheet

Executive Summary

Petaluma, Calif., company will launch the first hydrogen version of its Microcyn technology July 1. Microcyn Skin and Wound Hydrogel received FDA clearance in May for management of exuding wounds such as leg ulcers and diabetic ulcers, and for management of mechanically or surgically debrided wounds. In early June, Oculus announced its original Microcyn Skin and Wound Cleaner received 510(k) clearance for debridement of wounds such as stage I-IV pressure ulcers, partial and full thickness wounds, diabetic foot ulcers, post-surgical wounds, and first- and second-degree burns. During the company's June 11 fourth-quarter earnings call, Oculus CEO Hoji Alimi said studies have shown Microcyn technology to be effective in wound healing, but the company says it is not marketing the product for that claim. Oculus declined to say whether the company would seek a wound healing indication for Microcyn in the future
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT027605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel